Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (19591)	3/11/1999 2:48:00 PM
From: VLAD	Respond to of 23519

Dave, The guy who wrote that article is an uninformed jerk. It is too bad that as early as back in August he was slamming a company in his paper's area where people were losing their jobs. He is a disgrace to his community and an even bigger disgrace to nonbiased financial journalism. You can bet that the day will come when I write a nice long letter to the editor of the SFC pointing out a few things about this jerk that I find quite bothersome. In the mean time let's just let her ride....

To: DaiS who wrote (19591)	3/11/1999 3:12:00 PM
From: VLAD	Read Replies (3) \| Respond to of 23519

To all my fellow long term Vivus investors: Just thought I would make a list of all expected future positives for Vivus: Very near term(less than a month): 1)Approval/licensing of MUSE in France and Spain generating anothe $4M in milestone payment from Astra. 2)Confirmation on Edgar of insider buying of Vivus across the board. 3)FDA update on Viagra linked deaths which makes the safety profile of MUSE all the more attractive. 4)Astra share holders vote March 18th to approve merger with Zeneca. Near term(within next 2 months): 1)New coverage of Vivus initiated by at least one if not two new brokerages. 2)Q1 conference call which will again prove that Vivus is fiscally healthy and our new CFO is doing a great job keeping expenses in line with revenues. 3)MUSE launched in many EU countries. 4)A DOMESTIC PARTNER ANNOUNCED!!! Expect it to be Astra/Zeneca! 5)Further label changes in Viagra making MUSE market share more available. 6)Approval in Italy for another $2M. Longer term:(3 months or more) 1)A much more confident picture of Vivus as a profit generating biotech company as more international launches are initiated. 2)Alibra finishes very successful phase III trials and NDA submitted. 3)MUSE approved in China for a $2M milestone from Janssen and a launching into the most populous nation in the world and a $1 billion plus Chinese market! These are just SOME of the things to look forward to!

To: DaiS who wrote (19591)	3/11/1999 4:07:00 PM
From: blankmind	Read Replies (1) \| Respond to of 23519

"The maker of Muse, an also-ran male impotency treatment dwarfed by the gonzo success of Viagra, knocked a double on Monday after announcing that it won a patent for a topical cream aimed at helping women with sexual dysfunction. " - you're right, Dais, very negative article. - I just hoped it caused some more shorting